Kailera Therapeutics, Inc. (KLRA)
NASDAQ
Healthcare
Biotechnology
$21.81
▲ +4.70%
Market Cap
$2.83B
Sector
Healthcare
Industry
Biotechnology
Beta
0.00
52-Wk Range
18.5-28.23
CEO
Ronald C. Renaud Jr.
Country
US
Currency
USD
Kailera Therapeutics is a biopharmaceutical company currently advancing through its clinical development stage, dedicated to cultivating a varied portfolio of cutting-edge treatments. These therapeutics are specifically engineered to tackle obesity and its associated metabolic disorders. The company distinguishes itself through its focus on innovative methodologies, offering both injectable and orally administered formulations for sustainable weight management. Its most advanced candidate is a groundbreaking dual-action gut hormone receptor agonist, which has reported encouraging outcomes in i…
Open full interactive analysis & DCF →